Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

In MVOR-1, 65% of patients treated with Emrosi achieved IGA success at week 16 compared with 46% of the doxycycline group (treatment difference, 18% [95% CI, 5-31]) and 31% of the placebo group ...

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

Here are the 10 best rates for CDs in November 2024. All of these accounts are protected by either the Federal Deposit ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Thanks for liking this story! We have added it to a list of your favorite stories. MPR News surveyed candidates in local, state and federal races, and voters in Minnesota can use our tool to get ...

A recent financial report released by MTN Nigeria has shown that the telecom business reported a loss after tax of N514.9 ...

题图 | Pixabay肺癌是全世界发病率最高的癌症之一，也是全世界癌症死亡的主要原因。在中国，肺癌的发病率占全球四分之一，肺癌也是中国癌症死亡的主要原因。2024年10月21日，百济神州宣布其PD-1抑制剂替雷利珠单抗新适应症上市申请获得中国国家药 ...

The approved of Vistaseal has been expanded to include use in pediatric patients as an adjunct to hemostasis for mild to moderate bleeding.

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.

【导读】肝细胞癌（HCC）伴大血管浸润（MVI）的患者预后不佳，没有标准的围手术期治疗。该2期试验旨在研究围手术期替雷利珠单抗联合调强放疗（IMRT）治疗MVI可切除HCC的活性和安全性。2024年10月29日，海军军医大学附属东方肝胆外科医院王若愚 ...

Furthermore, ordinal regression indicated that para athletes with neurological impairments were 147% more likely to experience a progression from ‘severe’ to ‘very severe’ UI (OR=2.47; 95% CI 1.59 ...